186 related articles for article (PubMed ID: 16326100)
21. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
de Alava E; Ocaña A; Abad M; Montero JC; Esparís-Ogando A; Rodríguez CA; Otero AP; Hernández T; Cruz JJ; Pandiella A
J Clin Oncol; 2007 Jul; 25(19):2656-63. PubMed ID: 17602072
[TBL] [Abstract][Full Text] [Related]
22. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
23. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
Hudelist G; Köstler WJ; Attems J; Czerwenka K; Müller R; Manavi M; Steger GG; Kubista E; Zielinski CC; Singer CF
Br J Cancer; 2003 Sep; 89(6):983-91. PubMed ID: 12966413
[TBL] [Abstract][Full Text] [Related]
24. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.
Robinson AG; Turbin D; Thomson T; Yorida E; Ellard S; Bajdik C; Huntsman D; Gelmon K
Clin Breast Cancer; 2006 Aug; 7(3):254-61. PubMed ID: 16942643
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
Köstler WJ; Steger GG; Soleiman A; Schwab B; Singer CF; Tomek S; Brodowicz T; Krainer M; Wiltschke C; Horvat R; Jakesz R; Zielinski CC
Anticancer Res; 2004; 24(2C):1127-30. PubMed ID: 15154635
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
[TBL] [Abstract][Full Text] [Related]
27. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
Kuroda N; Kontani K; Kajikawa T; Taminato T
Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
Bethune-Volters A; Labroquere M; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
Anticancer Res; 2004; 24(2C):1083-9. PubMed ID: 15154627
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
30. Targeting Her-2/neu in breast cancer: as easy as this!
Azim H; Azim HA
Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
[TBL] [Abstract][Full Text] [Related]
32. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
33. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
Hehl EM
Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
[TBL] [Abstract][Full Text] [Related]
34. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
35. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
36. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
Hanna W; Kahn HJ; Trudeau M
Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
[TBL] [Abstract][Full Text] [Related]
38. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
[TBL] [Abstract][Full Text] [Related]
39. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
40. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
